# Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma

> **NCT01833299** · PHASE3 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 120 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Face Cancer

## Interventions

- **PROCEDURE:** TACE-Sorafenib group
- **PROCEDURE:** TACE

## Key facts

- **NCT ID:** NCT01833299
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2016-12
- **Final completion:** 2018-12
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2020-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01833299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01833299, "Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01833299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*